Polyribosome targets mediating mRNA decay for cancer prediction and therapy
Polyribosome targets mediating mRNA decay for cancer prediction and therapy
批准号:
8189284
负责人:
Christopher Benz
金额:
$21.1万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30
关键词:
3&apos Untranslated RegionsAcetylationBiological MarkersBreast Cancer CellCellsCompanionsDevelopmentERBB2 geneEpigenetic ProcessGrowthHistone deacetylase inhibitionMalignant NeoplasmsMass Spectrum AnalysisMediatingMessenger RNANormal tissue morphologyOncogenesOncogenicPhenotypePolyribosomesPost-Translational Protein ProcessingProcessProtein IsoformsProteinsRNA InterferenceResearchResolutionRoleTechniquesTherapeuticTranscriptTwo-Dimensional Gel ElectrophoresisValidationanticancer researchbasecancer cellcancer therapydesigninnovationmRNA Decaymalignant breast neoplasmnew therapeutic targetnoveloverexpressiontherapeutic targettreatment strategy
中文摘要
描述(由申请人提供):这个R21项目旨在识别和表征新的靶标和生物标记物,这些标记物涉及以前未被认识到的促进致癌转录本快速衰退的细胞机制。虽然细胞中的所有蛋白质都是由它们各自的转录本(MRNAs)产生的,但那些编码促癌蛋白的蛋白质通常在其3‘非翻译区具有独特的区别特征。致癌mRNAs的这些显著特征允许它们的稳定性和过度表达(例如,在癌症发展过程中),或它们的衰变和破坏(例如,在正常组织成熟期间)。我们的初步研究表明,当多聚核糖体相关并且蛋白质受到翻译后修饰(如乙酰化)的影响时,促癌基因的破坏就会发生。重要的是,将这种mRNA破坏机制划分为多聚核糖体有助于寻找调节这种转换的蛋白质异构体,揭示新的癌症治疗靶点。已知的表观遗传疗法,如组蛋白脱乙酰酶抑制,可以迅速诱导ERBB2和其他癌基因转录本的加速衰退,可能是通过诱导多聚体蛋白翻译后修饰来实现的。第一个项目的目标是通过质谱仪(MS)从乳腺癌细胞中分离和鉴定其癌基因转录破坏开关被组蛋白脱乙酰酶抑制激活的多聚核糖体蛋白亚型。第二个项目的目的是利用RNA干扰(RNAi)技术来验证候选的多聚核糖体蛋白靶标,这些靶标被证明在调控癌症生长以及癌基因转录破坏机制方面是必不可少的。该项目将生成一份充分表征、验证和优先排序的多聚核糖体蛋白靶标和生物标记物的清单,这些靶标和生物标记物已知可以调节癌症生长和癌基因转录稳定性。这份清单将包含最有希望的多核糖体异构体,用于预测和靶向一类全新的癌症治疗药物,这种药物通过诱导转录衰退来选择性地关闭促癌蛋白。
公共卫生相关性:癌症研究的一个优先问题是需要更具创新性的癌症治疗策略及其伴随的预测生物标记物。这一提议背后的假设是,可以基于靶向先前未知的多核糖体内细胞机制中的关键成分来开发一种全新的癌症治疗策略,该机制调节决定癌基因转录稳定性或其破坏的开关。利用最近开发的灵敏的多聚体图谱和基于质谱学的方法,我们将发现并确认调节这一开关的新的多聚体蛋白亚型的作用。这些新的治疗靶点和预测生物标记物的发现和验证将推动一类创新癌症治疗药物的发展,这些药物能够通过加速转录衰退来选择性地关闭促癌蛋白。
英文摘要
DESCRIPTION (provided by applicant): This R21 project aims to identify and characterize novel targets and biomarkers involved in a previously unrecognized cellular mechanism promoting the rapid decay of oncogenic transcripts. While all proteins in a cell are produced from their respective transcripts (mRNAs), those encoding cancer promoting proteins typically carry unique distinguishing features in their 3' untranslated regions. These distinguishing features of oncogenic mRNAs allow for their stability and overexpression (e.g. during cancer development), or for their decay and destruction (e.g. during normal tissue maturation). Our preliminary research has shown that destruction of the cancer promoting mRNA occurs while it is polyribosome associated and where proteins are subject to post-translational modifications like acetylation. Importantly, compartmentalization of this mRNA destruction machinery to the polyribosome facilitates a search for protein isoforms that regulate this switch, revealing novel cancer therapeutic targets. It is known that epigenetic therapy such as histone deacetylase inhibition rapidly induces accelerated decay of ERBB2 and other oncogenic transcripts, putatively via induction of polysome protein post-translational modifications. The first project aim is to isolate and identify by mass spectrometry (MS) polyribosome protein isoforms from breast cancer cells that have their oncogene transcript destruction switch activated by histone deacetylase inhibition. The second project aim is to validate candidate polyribosome protein targets that are demonstrated to be essential in regulating cancer growth as well as the oncogene transcript destruction mechanism, using the technique of RNA interference (RNAi). This project will generate a list of fully characterized, validated, and prioritized polyribosome protein targets and biomarkers known to regulate cancer growth and oncogene transcript stability. This list will contain the most promising polyribosome isoforms for prediction and targeting of an entirely new class of cancer therapeutics that selectively turn off cancer-promoting proteins by inducing their transcript decay.
PUBLIC HEALTH RELEVANCE: A priority issue for cancer research is the need for more innovative cancer treatment strategies and their companion predictive biomarkers. The hypothesis underlying this proposal is that an entirely new cancer treatment strategy can be developed based on targeting key components in a previously unrecognized cellular mechanism within polyribosomes that regulates a switch determining either oncogene transcript stability or its destruction. Using a sensitive and recently developed polysome profiling and mass spectrometry-based approach, we will discover and confirm the role of novel polysome protein isoforms that regulate this switch. The discovery and validation of these novel therapeutic targets and predictive biomarkers will drive the development of an innovative class of cancer therapeutics capable of selectively turning off cancer-promoting proteins by accelerating their transcript decay.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UCSC-Buck Genome Data Analysis Center for the Genomic Data Analysis Network v2.0
-
批准号:10671031
-
项目类别:
-
资助金额:$30.66万
-
财政年份:2021
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Genome Data Analysis Center for the Genomic Data Analysis Network v2.0
-
批准号:10300936
-
项目类别:
-
资助金额:$41.29万
-
财政年份:2021
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Genome Data Analysis Center for the Genomic Data Analysis Network v2.0
-
批准号:10483164
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2021
-
负责人:Christopher Benz
-
依托单位:
Polyribosome targets mediating mRNA decay for cancer prediction and therapy
-
批准号:8287560
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2011
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:7942768
-
项目类别:
-
资助金额:$108.49万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:7789014
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:8117695
-
项目类别:
-
资助金额:$131.21万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:8537845
-
项目类别:
-
资助金额:$187.8万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:8309386
-
项目类别:
-
资助金额:$130.95万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:8925188
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)
-
批准号:8827877
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2009
-
负责人:Christopher Benz
-
依托单位:
CLINICAL SIGNIFICANCE OF FUNCTIONALLY DEFECTIVE ESTROGEN RECEPTOR
-
批准号:7724158
-
项目类别:
-
资助金额:$0.59万
-
财政年份:2008
-
负责人:Christopher Benz
-
依托单位:
CLINICAL SIGNIFICANCE OF FUNCTIONALLY DEFECTIVE ESTROGEN RECEPTOR
-
批准号:7601809
-
项目类别:
-
资助金额:$2.52万
-
财政年份:2007
-
负责人:Christopher Benz
-
依托单位:
CLINICAL SIGNIFICANCE OF FUNCTIONALLY DEFECTIVE ESTROGEN RECEPTOR
-
批准号:7369031
-
项目类别:
-
资助金额:$1.32万
-
财政年份:2006
-
负责人:Christopher Benz
-
依托单位:
ECOLOGICAL & CLIN SIG OF DEFECTIVE ESTROGEN RECEPTOR FROM HUMAN BREAST TUMOR
-
批准号:7180912
-
项目类别:
-
资助金额:$2.05万
-
财政年份:2005
-
负责人:Christopher Benz
-
依托单位:
ECOLOGICAL & CLIN SIG OF DEFECTIVE ESTROGEN RECEPTOR
-
批准号:6976599
-
项目类别:
-
资助金额:$1.78万
-
财政年份:2004
-
负责人:Christopher Benz
-
依托单位:
Biology of Breast Cancers Arising in Older Women
-
批准号:7090081
-
项目类别:
-
资助金额:$56.06万
-
财政年份:2003
-
负责人:Christopher Benz
-
依托单位:
Biology of Breast Cancers Arising in Older Women
-
批准号:7258976
-
项目类别:
-
资助金额:$55.83万
-
财政年份:2003
-
负责人:Christopher Benz
-
依托单位:
Biology of Breast Cancers Arising in Older Women
-
批准号:6901838
-
项目类别:
-
资助金额:$56.47万
-
财政年份:2003
-
负责人:Christopher Benz
-
依托单位:
Biology of Breast Cancers Arising in Older Women
-
批准号:6606452
-
项目类别:
-
资助金额:$56.24万
-
财政年份:2003
-
负责人:Christopher Benz
-
依托单位:
海外基金